JDD April 2024 Issue Highlights
Introducing the April 2024 Editorial Highlights from the Journal of Drugs in Dermatology! This month's issue is packed with groundbreaking research and insights into dermatologic treatments and practices. From original articles exploring innovative therapies for conditions like photoaging and acne vulgaris to case reports shedding light on rare dermatologic phenomena, this issue offers a comprehen …
Introducing the April 2024 Editorial Highlights from the Journal of Drugs in Dermatology! This month's issue is packed with groundbreaking research and insights into dermatologic treatments and practices. From original articles exploring innovative therapies for conditions like photoaging and acne vulgaris to case reports shedding light on rare dermatologic phenomena, this issue offers a comprehen … 
The latest buzz word in hidradenitis suppurativa treatment is combination. Without a single, consistently and widely effective therapy, it’s important to build your own regimen by combining treatments, says Dr. Steven Daveluy, associate professor of dermatology and residency program director at Wayne State University School of Medicine. Next Steps in Derm, in partnership with ODAC Dermatology, A … 
During the 2023 Skin of Color Update in New York City, Dr. Omar Ibrahimi, a renowned laser and cosmetic dermatologist, as well as a Mohs surgeon in private practice in Stamford, Connecticut, imparted valuable insights into the use of lasers for pigmented lesions and tattoos. Dr. Ibrahimi placed significant emphasis on ensuring both safety and efficacy, particularly in individuals with diverse skin … 
March into groundbreaking dermatological insights with the latest issue of the Journal of Drugs in Dermatology! Explore the prescribing habits of oral minoxidil for androgenetic alopecia, delve into a comprehensive review of botulinum toxin uses, and discover the effectiveness of microneedling for acne scars. Plus, unravel the uncertainties surrounding exosome therapy in androgenetic alopecia. Fro … 
Oxymetazoline is an adrenoreceptor agonist which is FDA-approved for dermatologic conditions including persistent facial erythema in rosacea and blepharoptosis. Functioning primarily as a vasoconstrictor with additional anti-inflammatory properties, oxymetazoline targets the sustained vasodilated state of cutaneous blood vessels in rosacea by inducing vasoconstriction and reducing the persistent f … 